VEA
Virtus ETF Advisers’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,702
| Closed | -$303K | – | 371 |
|
|
2024
Q4 | $303K | Buy |
7,702
+2,655
| +53% | +$105K | 0.12% | 245 |
|
|
2024
Q3 | $237K | Hold |
5,047
| – | – | 0.11% | 242 |
|
|
2024
Q2 | $273K | Sell |
5,047
-1,007
| -17% | -$54.4K | 0.13% | 239 |
|
|
2024
Q1 | $413K | Buy |
6,054
+871
| +17% | +$59.4K | 0.22% | 191 |
|
|
2023
Q4 | $324K | Buy |
5,183
+3,502
| +208% | +$219K | 0.21% | 213 |
|
|
2023
Q3 | $76.3K | Sell |
1,681
-163
| -9% | -$7.4K | 0.05% | 369 |
|
|
2023
Q2 | $104K | Sell |
1,844
-173
| -9% | -$9.71K | 0.06% | 365 |
|
|
2023
Q1 | $91.2K | Sell |
2,017
-774
| -28% | -$35K | 0.05% | 358 |
|
|
2022
Q4 | $113K | Buy |
2,791
+996
| +55% | +$40.5K | 0.06% | 432 |
|
|
2022
Q3 | $117K | Buy |
1,795
+11
| +0.6% | +$717 | 0.05% | 402 |
|
|
2022
Q2 | $108K | Sell |
1,784
-297
| -14% | -$18K | 0.04% | 413 |
|
|
2022
Q1 | $131K | Sell |
2,081
-122
| -6% | -$7.68K | 0.06% | 247 |
|
|
2021
Q4 | $167K | Buy |
2,203
+559
| +34% | +$42.4K | 0.06% | 299 |
|
|
2021
Q3 | $184K | Sell |
1,644
-93
| -5% | -$10.4K | 0.08% | 292 |
|
|
2021
Q2 | $281K | Sell |
1,737
-266
| -13% | -$43K | 0.12% | 203 |
|
|
2021
Q1 | $244K | Buy |
2,003
+37
| +2% | +$4.51K | 0.1% | 293 |
|
|
2020
Q4 | $301K | Sell |
1,966
-3,189
| -62% | -$488K | 0.12% | 209 |
|
|
2020
Q3 | $431K | Sell |
5,155
-689
| -12% | -$57.6K | 0.23% | 154 |
|
|
2020
Q2 | $429K | Buy |
5,844
+347
| +6% | +$25.5K | 0.2% | 172 |
|
|
2020
Q1 | $233K | Sell |
5,497
-809
| -13% | -$34.3K | 0.1% | 262 |
|
|
2019
Q4 | $384K | Buy |
+6,306
| New | +$384K | 0.06% | 273 |
|